BioNTech SE

As of June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR carries a market capitalization of 122.45B, placing it among publicly traded companies globally. Its enterprise value stands at 37.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR has 4.03B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.71, and the price-to-book ratio stands at 1.17.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 37.04B versus a market cap of 122.45B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR maintains a current ratio of 7.85, meaning it holds 7.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.78, indicating elevated leverage, while an interest coverage ratio of -175.85 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR posted a negative return on equity (ROE) of -9.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.03, reflecting losses generated across the asset base. The company generates approximately 2.07M in revenue per employee across its workforce of 7,548.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.92 indicates how many times BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR recorded 336.02M in income tax expense. The company reported a pretax loss of -9.62B and -9.96B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR's stock has declined approximately 19.18% over the past 52 weeks. The 50-day moving average sits at 31.55, while the 200-day moving average is 31.37.

Over the twelve months ended June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR generated 15.65B in revenue and converted that into -9.96B in net income, yielding earnings per share of -2.51. EBITDA reached -7.79B, while operating income came in at -7.30B.

As of June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR holds 87.27B in cash and equivalents against 1.87B in total debt, resulting in a net debt position of -55.66B. Total book value stands at 104.87B, with working capital of 78.83B providing operational flexibility.

BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR produced 4.01B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.39B in capital expenditures, free cash flow totaled 2.63B - equivalent to 0.66 per share.

Over the twelve months ended June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR posted a gross margin of 75.47, reflecting its pricing power and cost economics. The operating margin of -46.66 and net profit margin of -63.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 2.18, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.52, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR shareholders.

BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR's most recent stock split took place on November 21, 2022 with a 1:2 split ratio.

As of June 30, 2026, BioNTech SE ADR Unsponsored Brazilian Depositary Receipt Repr 0.0625 ADR has an Altman Z-Score of 6.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.